Skin Atlas
Skin Atlas
Indication1

Foslevodopa/foscarbidopa solution is indicated for the treatment of motor fluctuations in patients with advanced levodopa-responsive Parkinson’s disease (PD) who do not have satisfactory control of severe, debilitating motor fluctuations and hyper-/dyskinesia despite optimized treatment with available combinations of PD medicinal products.

Foslevodopa/foscarbidopa should only be prescribed by neurologists who are experienced in the treatment of patients with PD.


Administration1

Foslevodopa/foscarbidopa is administered via 24-hour continuous SC infusion, in the abdomen, avoiding a 5-cm radius around the navel and not be infused into areas where the site is tender, bruised, red or hard to the touch.

The infusion set (cannula) can remain in place for up to 3 days.


Preparation and Equipment1

Employ aseptic technique for preparation and administration.

Use the VYAFUSER™ Pump and only sterile, single-use components (syringe, infusion set, vial adapter).

Click to open the product monograph

Product monograph

Note: this tool does not include all the information from the product monograph. Please refer to the complete document for more details about foslevodopa/foscarbidopa.
1. AbbVie Corporation. PrVYALEV™ Product Monograph. April 14, 2026/p5/Indications/p11/Administration. www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/VYALEV_PM_EN.pdf
SC, subcutaneous.